Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurotrophic Keratopathy

Interventions

DRUG: RGN-259
DRUG: Placebo

Sponsor

ReGenTree, LLC